Post-earnings recap
Reported
Tue, Apr 27, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that CRISPR Therapeutics continues to operate at a loss, with a notable EPS miss. The stock reacted negatively, dropping 1.97%, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's financial health and future direction without clear expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.51 | N/A | -4.07% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter but emphasized their commitment to ongoing research and development. They did not provide specific guidance, reflecting a cautious approach.
Management did not provide specific guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the current losses.